Cochrane Summaries

Trusted evidence. Informed decisions. Better health.

Cabergoline to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction technology

Tang H, Hunter T, Hu Y, Zhai S-D, Sheng X, Hart RJ
Published Online: 
15 February 2012

Ovarian hyperstimulation syndrome (OHSS) occurs as a result of ovulation induction in assisted reproduction technology (ART) treatment. In most cases the condition is mild, but some women get a moderate or severe form of OHSS. The symptoms range from abdominal bloating and a feeling of fullness to shortness of breath and severe abdominal discomfort. Despite measures adopted by physicians to prevent OHSS, these measures are purely preventative as there is no cure for OHSS other than awaiting spontaneous resolution and providing supportive measures. A dopamine agonist cabergoline has been introduced to try and reduce the risk of OHSS. This review included two trials with moderate risk of bias (involving 230 women) and found evidence that an oral dose of 0.5 mg cabergoline daily may reduce the risk of OHSS in high-risk women, especially moderate OHSS. It had no influence on the pregnancy outcome.

This record should be cited as: 
Tang H, Hunter T, Hu Y, Zhai S-D, Sheng X, Hart RJ. Cabergoline for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews 2012, Issue 2. Art. No.: CD008605. DOI: 10.1002/14651858.CD008605.pub2
Assessed as up to date: 
2 September 2011